| Dr Wook S Kang, MD | |
|
9961 Sierra Ave, Department Of Emergency Medicine, Fontana, CA 92335-6720 | |
| (909) 427-7253 | |
| Not Available |
| Full Name | Dr Wook S Kang |
|---|---|
| Gender | Male |
| Speciality | Emergency Medicine |
| Experience | 19 Years |
| Location | 9961 Sierra Ave, Fontana, California |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1346459831 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207P00000X | Emergency Medicine | A103373 (California) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Kaiser Foundation Hospital Fontana/ontario | Fontana, CA | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Southern California Permanente Medical Group | 6002729175 | 7951 |
News Archive
A new study of patients who underwent curative surgical removal of a pancreatic ductal adenocarcinoma showed that two of the nine preoperative factors analyzed were strongly predictive of poor prognosis regardless of the tumor stage.
The Azrieli Foundation, the Canadian Institutes of Health Research, the International Development Research Centre, and the Israel Science Foundation are pleased to announce the recipients of the Joint Canada-Israel Health Research Program's 5th call for proposals.
Protalix BioTherapeutics, Inc. (NYSE-Amex:PLX), announced today that it has received notice from the U.S. Food and Drug Administration (FDA) that the FDA's Office of Orphan Products Development has granted orphan drug designation to prGCD, the Company's proprietary plant cell expressed recombinant form of glucocerebrosidase (GCD) for the treatment of Gaucher disease.
ImmunoCellular Therapeutics, Ltd., a biotechnology company that is developing immune based therapies for the treatment of various forms of cancer, announced today it received a Notice of Allowance from the United States Patent and Trademark Office covering technology relating to monoclonal antibodies that bind to certain epitopes present on pancreatic cancers. This patent will broaden the Company's proprietary intellectual property for ICT-109 and ICT-37, two of the Company's monoclonal antibody product candidates.
The Saban Research Institute recently hosted the 3rd annual Meaningful Use of Complex Medical Data (MUCMD) Symposium. Organized by Randall Wetzel, MD, chairman of the Department of Anesthesiology and Critical Care Medicine at Children's Hospital Los Angeles, MUCMD is a forum that fosters communication between physicians and "Big Data" experts in order to make use of the large amounts of medical data.
› Verified 1 days ago
| Entity Name | Southern California Permanente Medical Group |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1316979834 PECOS PAC ID: 6002729175 Enrollment ID: O20040126000823 |
News Archive
A new study of patients who underwent curative surgical removal of a pancreatic ductal adenocarcinoma showed that two of the nine preoperative factors analyzed were strongly predictive of poor prognosis regardless of the tumor stage.
The Azrieli Foundation, the Canadian Institutes of Health Research, the International Development Research Centre, and the Israel Science Foundation are pleased to announce the recipients of the Joint Canada-Israel Health Research Program's 5th call for proposals.
Protalix BioTherapeutics, Inc. (NYSE-Amex:PLX), announced today that it has received notice from the U.S. Food and Drug Administration (FDA) that the FDA's Office of Orphan Products Development has granted orphan drug designation to prGCD, the Company's proprietary plant cell expressed recombinant form of glucocerebrosidase (GCD) for the treatment of Gaucher disease.
ImmunoCellular Therapeutics, Ltd., a biotechnology company that is developing immune based therapies for the treatment of various forms of cancer, announced today it received a Notice of Allowance from the United States Patent and Trademark Office covering technology relating to monoclonal antibodies that bind to certain epitopes present on pancreatic cancers. This patent will broaden the Company's proprietary intellectual property for ICT-109 and ICT-37, two of the Company's monoclonal antibody product candidates.
The Saban Research Institute recently hosted the 3rd annual Meaningful Use of Complex Medical Data (MUCMD) Symposium. Organized by Randall Wetzel, MD, chairman of the Department of Anesthesiology and Critical Care Medicine at Children's Hospital Los Angeles, MUCMD is a forum that fosters communication between physicians and "Big Data" experts in order to make use of the large amounts of medical data.
› Verified 1 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Wook S Kang, MD 9961 Sierra Ave, Department Of Emergency Medicine, Fontana, CA 92335-6720 Ph: () - | Dr Wook S Kang, MD 9961 Sierra Ave, Department Of Emergency Medicine, Fontana, CA 92335-6720 Ph: (909) 427-7253 |
News Archive
A new study of patients who underwent curative surgical removal of a pancreatic ductal adenocarcinoma showed that two of the nine preoperative factors analyzed were strongly predictive of poor prognosis regardless of the tumor stage.
The Azrieli Foundation, the Canadian Institutes of Health Research, the International Development Research Centre, and the Israel Science Foundation are pleased to announce the recipients of the Joint Canada-Israel Health Research Program's 5th call for proposals.
Protalix BioTherapeutics, Inc. (NYSE-Amex:PLX), announced today that it has received notice from the U.S. Food and Drug Administration (FDA) that the FDA's Office of Orphan Products Development has granted orphan drug designation to prGCD, the Company's proprietary plant cell expressed recombinant form of glucocerebrosidase (GCD) for the treatment of Gaucher disease.
ImmunoCellular Therapeutics, Ltd., a biotechnology company that is developing immune based therapies for the treatment of various forms of cancer, announced today it received a Notice of Allowance from the United States Patent and Trademark Office covering technology relating to monoclonal antibodies that bind to certain epitopes present on pancreatic cancers. This patent will broaden the Company's proprietary intellectual property for ICT-109 and ICT-37, two of the Company's monoclonal antibody product candidates.
The Saban Research Institute recently hosted the 3rd annual Meaningful Use of Complex Medical Data (MUCMD) Symposium. Organized by Randall Wetzel, MD, chairman of the Department of Anesthesiology and Critical Care Medicine at Children's Hospital Los Angeles, MUCMD is a forum that fosters communication between physicians and "Big Data" experts in order to make use of the large amounts of medical data.
› Verified 1 days ago
Dr. Silas Chun-wing Chiu, M.D. Emergency Medicine Medicare: Medicare Enrolled Practice Location: 9961 Sierra Ave, Fontana, CA 92335 Phone: 909-427-5000 Fax: 310-782-1763 | |
Kim Trinh, M.D. Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 9961 Sierra Ave, Fontana, CA 92335 Phone: 951-333-1581 | |
Scott Alan Walker, MD Emergency Medicine Medicare: Medicare Enrolled Practice Location: 9961 Sierra Ave, Fontana, CA 92335 Phone: 909-427-3910 | |
Mr. Santiago Lopez Jr., Emergency Medicine Medicare: Medicare Enrolled Practice Location: 9961 Sierra Ave, Fontana, CA 92335 Phone: 833-574-2273 Fax: 833-574-2273 | |
Greg A. Capestany, MD Emergency Medicine Medicare: Not Enrolled in Medicare Practice Location: 9961 Sierra Ave, Fontana, CA 92335 Phone: 909-427-3910 | |
David G. Reiley, MD Emergency Medicine Medicare: Medicare Enrolled Practice Location: 9961 Sierra Ave, Fontana, CA 92335 Phone: 909-427-3910 | |
Dr. Tina Ann Nguyen, MD Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 9961 Sierra Ave, Fontana, CA 92335 Phone: 800-464-4000 |